Thailand's Foundation for Consumers has attacked a proposed free-trade agreement between the European Union and the Association of Southeast Asian Nations (ASEAN) that would effectively outlaw compulsory licensing and prohibit the marketing of copy drugs, even without a locally-valid patent. Jiraporn Limpananont, the Foundation's head, claims that Article 9 of the proposed EU-ASEAN FTA contains sweeping intellectual property rights protection for R&D drugmakers that go beyond the World Trade Organization's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs; Marketletters passim).
The Bangkok Post reported that this issue could contribute to public protests against the ASEAN's trade policy at the regional body's 14th annual summit in late February. Other elements of the proposed deal affecting agriculture are also considered controversial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze